Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 11, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,390	1,188	2,731	2,974	8,799	3,514
Market Cap Growth	29.36%	-56.51%	-8.18%	-66.20%	150.41%	390.02%
Enterprise Value	818	344	1,856	2,223	7,727	3,128
Last Close Price	12.00	11.66	30.49	34.89	118.24	54.40
PS Ratio	21.87	20.52	75.27	57.06	266.22	60.59
PB Ratio	1.86	1.36	2.60	2.41	8.46	6.67
P/TBV Ratio	1.86	1.36	2.60	2.41	8.46	6.67
EV/Sales Ratio	14.22	5.95	51.17	42.65	233.76	53.94
Debt / Equity Ratio	0.13	0.24	0.11	0.11	0.07	0.08
Asset Turnover	0.06	0.05	0.03	0.04	0.03	0.12
Quick Ratio	5.57	5.50	8.23	9.45	5.97	9.33
Current Ratio	6.21	5.77	8.66	9.62	6.11	9.60
Return on Equity (ROE)	-52.11%	-54.01%	-42.10%	-41.67%	-34.19%	-33.69%
Return on Assets (ROA)	-28.51%	-26.80%	-22.83%	-20.35%	-16.99%	-16.89%
Return on Capital Employed (ROCE)	-57.60%	-49.50%	-43.50%	-32.90%	-22.90%	-22.30%
Earnings Yield	-32.07%	-43.70%	-17.62%	-15.95%	-3.04%	-3.82%
FCF Yield	-29.69%	-29.87%	-14.95%	-11.66%	-2.70%	-1.52%
Buyback Yield / Dilution	-9.22%	-11.35%	-15.33%	-8.57%	-26.63%	-18.50%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q